Recombinant amyloid beta Antilichaam / APP

Proteolytic cleavage of the Amyloid protein precursor (APP) gives rise to the beta-Amyloid and Amyloid A4 proteins, which are present in human platelets. Amyloid deposition is associated with type II diabetes, Down syndrome and a variety of neurological disorders, including Alzheimer s disease. The Amyloid precursor protein (APP) undergoes alternative splicing, resulting in several isoforms. Proteolytic cleavage of APP leads to the formation of the 4 kDa Amyloid beta/A4 Amyloid protein. This protein is involved in the formation of neurofibrillary tangles and plaques that characterize the senile plaques of Alzheimer s patients. APLP1 (Amyloid precursor-like protein 1) and APLP2 are structurally similar to APP. Human APLP2 is a membrane-bound sperm protein that contains a region highly homologous to the transmembrane-cytoplasmic domains of APP found in brain plaques of Alzheimer s disease patients.

Immunohistochemistry (FFPE) : 1-2 µg/mL

P05067

Human

A portion of amino acids 500-700 from human APP protein was used as the immunogen for the recombinant Amyloid beta antibody.

APP/9971R

IHC-P

Protein A affinity

Purified

This recombinant Amyloid beta antibody is available for research use only.

Aliquot the recombinant Amyloid beta antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05% sodium azide

Optimal dilution of the recombinant Amyloid beta antibody should be determined by the researcher.

Membrane, cytoplasm

IHC staining of FFPE human brain tissue with recombinant Amyloid beta antibody (clone APP/9971R) . Inset: PBS used in place of primary Ab (secondary Ab negative control) . HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.